Biotechnology
Revolution Medicines' pan-RAS inhibitor daraxonrasib delivered a median overall survival of 13.2 months in metastatic pancreatic cancer—nearly doubling survival compared to standard chemotherapy. This Phase 3 breakthrough could reshape treatment paradigms for RAS-driven cancers.
Pharmaceuticals
The FDA faces its PDUFA deadline today on Travere Therapeutics' FILSPARI (sparsentan) for FSGS. If approved, it would be the first-ever therapy indicated for this rare, devastating kidney disease affecting 40,000 Americans.
Policy
Steve Ubl's announcement that he will step down as president and CEO of PhRMA signals that the political architecture the pharmaceutical industry built over the past decade is under unprecedented stress.
Pharmaceuticals
Novo Nordisk launched Wegovy HD at $399 per month, undercutting Lilly's Zepbound by $50. The move signals a new phase in the GLP-1 market where pricing strategy and clinical differentiation are becoming inseparable.
Biotechnology
Gilead Sciences is acquiring German ADC biotech Tubulis for up to $5 billion, its third major oncology deal in 2026. The transaction reveals why antibody-drug conjugates have become the most fiercely contested technology platform in cancer drug development.
Biotechnology
Neurocrine Biosciences is paying $2.9 billion for Soleno Therapeutics and its first-in-class hyperphagia drug Vykat XR. The deal reveals how rare disease M&A works when the science finally catches up to a condition that has been waiting decades for a targeted therapy.
Biotechnology
Biogen's $5.6 billion acquisition of Apellis Pharmaceuticals signals a strategic shift from neuroscience to immunology and rare disease, revealing new patterns in biotech M&A and corporate reinvention.
Policy
Trump's executive order imposing 100% tariffs on imported branded pharmaceuticals marks a structural turning point for the industry. Here is what the order actually says, who it protects, and what it risks.
Biotechnology
Eli Lilly's $6.3 billion acquisition of Centessa Pharmaceuticals signals a major pharmaceutical bet on orexin receptor biology and sleep medicine—revealing where the industry's capital is flowing beyond the GLP-1 wave.
Pharmaceuticals
Merck's enlicitide data from the CORALreef AddOn trial demonstrates that an oral PCSK9 inhibitor can achieve injectable-like LDL reductions of 64.6%, potentially transforming cholesterol management by eliminating the injection barrier that has limited patient access for over a decade.
Biotechnology
Eli Lilly's $2.75 billion commitment to Insilico Medicine represents the most significant commercial validation of AI drug discovery to date—a bet on proven capability, not theoretical potential.
Biotechnology
Bristol Myers Squibb's SCOUT-HCM trial demonstrates that Camzyos (mavacamten) is effective and safe in adolescents with obstructive hypertrophic cardiomyopathy, marking the first Phase 3 trial of a cardiac myosin inhibitor in a pediatric population and reshaping treatment options for young patients.